Review



myoblast basal media  (PromoCell)


Bioz Verified Symbol PromoCell is a verified supplier
Bioz Manufacturer Symbol PromoCell manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 96

    Structured Review

    PromoCell myoblast basal media
    Myoblast Basal Media, supplied by PromoCell, used in various techniques. Bioz Stars score: 96/100, based on 359 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/growth+media+skeletal+muscle+cell+basal+medium/us12496301-573-29-32?v=PromoCell
    Average 96 stars, based on 359 article reviews
    myoblast basal media - by Bioz Stars, 2026-07
    96/100 stars

    Images



    Similar Products

    96
    PromoCell myoblast basal media
    Myoblast Basal Media, supplied by PromoCell, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/growth+media+skeletal+muscle+cell+basal+medium/us12496301-573-29-32?v=PromoCell
    Average 96 stars, based on 1 article reviews
    myoblast basal media - by Bioz Stars, 2026-07
    96/100 stars
      Buy from Supplier

    94
    PromoCell growth media skeletal muscle cell basal medium
    Growth Media Skeletal Muscle Cell Basal Medium, supplied by PromoCell, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/growth+media+skeletal+muscle+cell+basal+medium/pm41287112-496-85-94?v=PromoCell
    Average 94 stars, based on 1 article reviews
    growth media skeletal muscle cell basal medium - by Bioz Stars, 2026-07
    94/100 stars
      Buy from Supplier

    94
    PromoCell immortalized 2d myotube after seeding growth media
    IMNM autoantibodies induce hMMT <t>myotube</t> atrophy. A Representative 40x confocal images of myotubes formed in hMMTs within each condition immunostained for sarcomeric α-actinin (SAA, magenta) and counterstained with Hoechst 33,342 (cyan). Scale bar = 50 μm. B Dot plot of hMMT nuclear fusion index for individual hMMTs. C Dot plot of mean SAA positive coverage within flattened confocal stack images for individual hMMTs. D Dot plot of myotube width variation as quantified by the coefficient of variance for single myotubes. n = 146 for (+) and (-) healthy IgG, n = 138 for Ceri, n = 524 for anti-HMGCR, and n = 550 for anti-SRP. E Histogram illustrating myotube diameter frequency across treatment conditions. F Dot plot showing average myotube diameter for individual hMMTs. N = 7 patients for anti-HMGCR + and N = 7 for anti-SRP + IgG treatments. Cerivastatin (Ceri, 75 nM) treatment served as a positive control and no added IgG (-) or Healthy IgG treatment served as negative controls. n = 3 hMMTs per treatment condition. Samples were tested across N = 2 independent experiments which are distinguished in graphs by circle and triangle datapoints. Data for hMMTs treated with total IgGs are binned according to whether they induced a direct contractile effect (DCE; HP2-4 and SP5) or no contractile effect (NCE; HP1, 5–7 and SP1-4, 6, 7) on hMMT force production as indicated by the data in Fig. . All values are reported as means \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document} SEM; * p < 0.05,** p < 0.01, *** p < 0.001, and **** p < 0.0001
    Immortalized 2d Myotube After Seeding Growth Media, supplied by PromoCell, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/growth+media+skeletal+muscle+cell+basal+medium/pmc12882220-33-0-15?v=PromoCell
    Average 94 stars, based on 1 article reviews
    immortalized 2d myotube after seeding growth media - by Bioz Stars, 2026-07
    94/100 stars
      Buy from Supplier

    Image Search Results


    IMNM autoantibodies induce hMMT myotube atrophy. A Representative 40x confocal images of myotubes formed in hMMTs within each condition immunostained for sarcomeric α-actinin (SAA, magenta) and counterstained with Hoechst 33,342 (cyan). Scale bar = 50 μm. B Dot plot of hMMT nuclear fusion index for individual hMMTs. C Dot plot of mean SAA positive coverage within flattened confocal stack images for individual hMMTs. D Dot plot of myotube width variation as quantified by the coefficient of variance for single myotubes. n = 146 for (+) and (-) healthy IgG, n = 138 for Ceri, n = 524 for anti-HMGCR, and n = 550 for anti-SRP. E Histogram illustrating myotube diameter frequency across treatment conditions. F Dot plot showing average myotube diameter for individual hMMTs. N = 7 patients for anti-HMGCR + and N = 7 for anti-SRP + IgG treatments. Cerivastatin (Ceri, 75 nM) treatment served as a positive control and no added IgG (-) or Healthy IgG treatment served as negative controls. n = 3 hMMTs per treatment condition. Samples were tested across N = 2 independent experiments which are distinguished in graphs by circle and triangle datapoints. Data for hMMTs treated with total IgGs are binned according to whether they induced a direct contractile effect (DCE; HP2-4 and SP5) or no contractile effect (NCE; HP1, 5–7 and SP1-4, 6, 7) on hMMT force production as indicated by the data in Fig. . All values are reported as means \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document} SEM; * p < 0.05,** p < 0.01, *** p < 0.001, and **** p < 0.0001

    Journal: Skeletal Muscle

    Article Title: Complement-independent pathogenic influences of anti-HMGCR + and anti-SRP + immune-mediated necrotizing myopathy autoantibodies on engineered muscle function

    doi: 10.1186/s13395-025-00400-7

    Figure Lengend Snippet: IMNM autoantibodies induce hMMT myotube atrophy. A Representative 40x confocal images of myotubes formed in hMMTs within each condition immunostained for sarcomeric α-actinin (SAA, magenta) and counterstained with Hoechst 33,342 (cyan). Scale bar = 50 μm. B Dot plot of hMMT nuclear fusion index for individual hMMTs. C Dot plot of mean SAA positive coverage within flattened confocal stack images for individual hMMTs. D Dot plot of myotube width variation as quantified by the coefficient of variance for single myotubes. n = 146 for (+) and (-) healthy IgG, n = 138 for Ceri, n = 524 for anti-HMGCR, and n = 550 for anti-SRP. E Histogram illustrating myotube diameter frequency across treatment conditions. F Dot plot showing average myotube diameter for individual hMMTs. N = 7 patients for anti-HMGCR + and N = 7 for anti-SRP + IgG treatments. Cerivastatin (Ceri, 75 nM) treatment served as a positive control and no added IgG (-) or Healthy IgG treatment served as negative controls. n = 3 hMMTs per treatment condition. Samples were tested across N = 2 independent experiments which are distinguished in graphs by circle and triangle datapoints. Data for hMMTs treated with total IgGs are binned according to whether they induced a direct contractile effect (DCE; HP2-4 and SP5) or no contractile effect (NCE; HP1, 5–7 and SP1-4, 6, 7) on hMMT force production as indicated by the data in Fig. . All values are reported as means \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document} SEM; * p < 0.05,** p < 0.01, *** p < 0.001, and **** p < 0.0001

    Article Snippet: Immortalized 2D myotube after seeding growth media , Skeletal Muscle Cell Basal Medium (Cat. #C-23260, Promo-Cell), 20% FBS, 1% P/S.

    Techniques: Positive Control

    Sarcomere structures are disrupted after mechanical load. A Left panel shows a representative 40x confocal image of hMMT myotubes post electrical field stimulation immunostained for sarcomeric α-actinin (SAA, magenta) and f-actin (actin, yellow) which corresponds to the input for the ZlineDetection program. Scale bar = 50 μm. Middle panel shows a corresponding output from the ZLineDetection program with a further zoom in (right panel) to illustrate the retention of striations following a mechanical load under control conditions. B - E Dot plots of mean ( B ) Z-lines per image, ( C ) continuous Z-line length, ( D ) sarcomere length, and ( E ) orientation order parameter (OOP). N = 7 patients for anti-HMGCR + and N = 7 patients for anti-SRP + IgG treatments. Cerivastatin (Ceri, 75 nM) treatment served as a positive control and no added IgG (-) or Healthy IgG treatment served as negative controls. n = 3 hMMTs per treatment condition. Samples were tested across N = 2 independent experiments which are distinguished in graphs by circle and triangle datapoints. Data for hMMTs treated with total IgGs are binned according to whether they induced a direct contractile effect (DCE; HP2-4 and SP5) or no contractile effect (NCE; HP1, 5–7 and SP1-4, 6, 7) on hMMT force production as indicated by the data in Fig. . All values are reported as means \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document} SEM; * p ≤ 0.05

    Journal: Skeletal Muscle

    Article Title: Complement-independent pathogenic influences of anti-HMGCR + and anti-SRP + immune-mediated necrotizing myopathy autoantibodies on engineered muscle function

    doi: 10.1186/s13395-025-00400-7

    Figure Lengend Snippet: Sarcomere structures are disrupted after mechanical load. A Left panel shows a representative 40x confocal image of hMMT myotubes post electrical field stimulation immunostained for sarcomeric α-actinin (SAA, magenta) and f-actin (actin, yellow) which corresponds to the input for the ZlineDetection program. Scale bar = 50 μm. Middle panel shows a corresponding output from the ZLineDetection program with a further zoom in (right panel) to illustrate the retention of striations following a mechanical load under control conditions. B - E Dot plots of mean ( B ) Z-lines per image, ( C ) continuous Z-line length, ( D ) sarcomere length, and ( E ) orientation order parameter (OOP). N = 7 patients for anti-HMGCR + and N = 7 patients for anti-SRP + IgG treatments. Cerivastatin (Ceri, 75 nM) treatment served as a positive control and no added IgG (-) or Healthy IgG treatment served as negative controls. n = 3 hMMTs per treatment condition. Samples were tested across N = 2 independent experiments which are distinguished in graphs by circle and triangle datapoints. Data for hMMTs treated with total IgGs are binned according to whether they induced a direct contractile effect (DCE; HP2-4 and SP5) or no contractile effect (NCE; HP1, 5–7 and SP1-4, 6, 7) on hMMT force production as indicated by the data in Fig. . All values are reported as means \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document} SEM; * p ≤ 0.05

    Article Snippet: Immortalized 2D myotube after seeding growth media , Skeletal Muscle Cell Basal Medium (Cat. #C-23260, Promo-Cell), 20% FBS, 1% P/S.

    Techniques: Control, Positive Control

    IMNM patient autoantibodies enter immortalized myoblast-derived myotubes in 2-D culture. A Representative z-projection (far right image) and single confocal slices (far left and middle images) of an immortalized myoblast-derived myotube in 2-D culture that was treated with total IgG from a healthy donor or an IMNM patient with HMGCR+ (HP4) or SRP+ (SP5) autoantibodies and then immunostained for anti-human IgG (magenta), sarcomeric α-actinin (SAA, cyan) and a Hoechst nuclear counterstain (gray). Scale bar = 20 μm. B Dot plot displaying mean human IgG immunostaining intensity quantified for individual regions of interest in immortalized myoblast-derived myotubes treated with total IgGs. N = 7 patients for anti-HMGCR + IgG treatments (anti-HMGCR Patient 1 [HP1], anti-HMGCR Patient 2 [HP2], and anti-HMGCR Patient 3 [HP3] and so on) and N = 7 patients for anti-SRP + IgG treatments (anti-SRP Patient 1 [SP1], anti-SRP Patient 2 [SP2], and anti-SRP Patient 3 [SP3] and so on). All values are reported as means \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document} SEM; ** p < 0.01 and **** p < 0.0001

    Journal: Skeletal Muscle

    Article Title: Complement-independent pathogenic influences of anti-HMGCR + and anti-SRP + immune-mediated necrotizing myopathy autoantibodies on engineered muscle function

    doi: 10.1186/s13395-025-00400-7

    Figure Lengend Snippet: IMNM patient autoantibodies enter immortalized myoblast-derived myotubes in 2-D culture. A Representative z-projection (far right image) and single confocal slices (far left and middle images) of an immortalized myoblast-derived myotube in 2-D culture that was treated with total IgG from a healthy donor or an IMNM patient with HMGCR+ (HP4) or SRP+ (SP5) autoantibodies and then immunostained for anti-human IgG (magenta), sarcomeric α-actinin (SAA, cyan) and a Hoechst nuclear counterstain (gray). Scale bar = 20 μm. B Dot plot displaying mean human IgG immunostaining intensity quantified for individual regions of interest in immortalized myoblast-derived myotubes treated with total IgGs. N = 7 patients for anti-HMGCR + IgG treatments (anti-HMGCR Patient 1 [HP1], anti-HMGCR Patient 2 [HP2], and anti-HMGCR Patient 3 [HP3] and so on) and N = 7 patients for anti-SRP + IgG treatments (anti-SRP Patient 1 [SP1], anti-SRP Patient 2 [SP2], and anti-SRP Patient 3 [SP3] and so on). All values are reported as means \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\pm\:$$\end{document} SEM; ** p < 0.01 and **** p < 0.0001

    Article Snippet: Immortalized 2D myotube after seeding growth media , Skeletal Muscle Cell Basal Medium (Cat. #C-23260, Promo-Cell), 20% FBS, 1% P/S.

    Techniques: Derivative Assay, Immunostaining